Use of Botulinum Toxin A (BoNT-A) in Detrusor External Sphincter Dyssynergia (DESD): A Systematic Review and Meta-analysis
- PMID: 32197987
- DOI: 10.1016/j.urology.2020.03.007
Use of Botulinum Toxin A (BoNT-A) in Detrusor External Sphincter Dyssynergia (DESD): A Systematic Review and Meta-analysis
Abstract
We performed a systematic review to examine the efficacy and outcomes of Botulinum Toxin A (BoNT-A) as the primary intervention strategy for patients with detrusor external sphincter dyssynergia. Eleven studies were included in the analysis (n = 353; 16% female, 84% male). BoNT-A was effective in 60%-78% of patients for reducing postvoid residual, mean detrusor pressure, detrusor leak point pressure, and mean urethral pressure 1 month after injection. Most patients required reinjection after an average of 4-9 months. BoNT-A was not associated with any significant adverse events, and may improve quality of life, as well as urodynamic parameters for detrusor external sphincter dyssynergia.
Copyright © 2020 Elsevier Inc. All rights reserved.
Comment in
-
Re: Goel S et al. Use of Botulinum Toxin A (BoNT-A) in Detrusor External Sphincter Dyssynergia (DESD): A Systematic Review and Meta-analysis. Urology. 2020. doi:10.1016/j.urology.2020.03.007.Urology. 2020 Oct;144:275-276. doi: 10.1016/j.urology.2020.05.078. Epub 2020 Jun 24. Urology. 2020. PMID: 32592765 No abstract available.
Similar articles
-
Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia.J Rehabil Med. 2016 Oct 5;48(8):683-687. doi: 10.2340/16501977-2132. J Rehabil Med. 2016. PMID: 27563834 Clinical Trial.
-
Predictors of outcome for urethral injection of botulinum toxin to treat detrusor sphincter dyssynergia in men with spinal cord injury.Spinal Cord. 2016 Jun;54(6):452-6. doi: 10.1038/sc.2015.224. Epub 2015 Dec 29. Spinal Cord. 2016. PMID: 26712037
-
Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion.Neurourol Urodyn. 2008;27(8):793-6. doi: 10.1002/nau.20606. Neurourol Urodyn. 2008. PMID: 18508331
-
Botulinum toxin as a new therapy option for voiding disorders: current state of the art.Eur Urol. 2003 Aug;44(2):165-74. doi: 10.1016/s0302-2838(03)00250-1. Eur Urol. 2003. PMID: 12875934 Review.
-
The Therapeutic Effects and Pathophysiology of Botulinum Toxin A on Voiding Dysfunction Due to Urethral Sphincter Dysfunction.Toxins (Basel). 2019 Dec 13;11(12):728. doi: 10.3390/toxins11120728. Toxins (Basel). 2019. PMID: 31847090 Free PMC article. Review.
Cited by
-
Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?Toxins (Basel). 2022 Jul 18;14(7):498. doi: 10.3390/toxins14070498. Toxins (Basel). 2022. PMID: 35878235 Free PMC article. Review.
-
The use of a percutaneous cystostomy tube as an adjunctive treatment option for dogs with idiopathic functional outflow tract obstruction.J Vet Intern Med. 2025 Jan-Feb;39(1):e17275. doi: 10.1111/jvim.17275. J Vet Intern Med. 2025. PMID: 39701563 Free PMC article.
-
Idiopathic functional urinary outflow tract obstruction in dogs, a retrospective case series (2010-2021): 31 cases.J Vet Intern Med. 2023 Nov-Dec;37(6):2211-2218. doi: 10.1111/jvim.16843. Epub 2023 Sep 29. J Vet Intern Med. 2023. PMID: 37775972 Free PMC article.
-
Conservative Bladder Management and Medical Treatment in Chronic Spinal Cord Injury Patients.J Clin Med. 2023 Mar 3;12(5):2021. doi: 10.3390/jcm12052021. J Clin Med. 2023. PMID: 36902808 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical